The progress made by biotechnology has shown that various factors and multiple signaling pathways are involved in the progression of cancer and other chronic disorders.
The progress made by biotechnology has shown that various factors and multiple signaling pathways are involved in the progression of cancer and other chronic disorders. Therefore, researchers believed targeting two or more signaling pathways simultaneously will lead to superior cytotoxic effects and will result in lower rate of resistance. This has led to advent of several multispecific antibodies which have the ability to bind to two or more epitopes simultaneously. Since then, several bispecific antibodies and trispecific antibodies have entered the clinical development and are indicated for the treatment of wide range of diseases including cancer, hemophilia, HIV, and other complex disorders.
As of now, the market for mulispecific antibodies is mainly dominated by bispecific antibodies. Three bispecific antibodies including Blincyto, Rybrevant, and Hemlibra are commercially available in the market and have shown high adoption rates. Among this, Hemlibra accounts for 80% of the share in the market. Apart from this, novel trispecific antibodies have also entered the clinical development and are mainly confined to phase-I/II clinical trials. GTB-3550 developed by GT Biopharma is one of the leading trispecific antibody construct indicated for the treatment of hematological malignancies. Furthermore, several other trispecific antibody constructs are present in clinical pipeline and are expected to enter the market during the forecast period.
Download Global Bispecific Antibody Market Insight 2028
Download Global Trispecific Antibody Market Opportunity And Clinical Trials Insight 2028 Report
A key factor driving the growth of the global multispecific antibodies for cancer market is the advantages of multispecific antibodies over monoclonal antibodies. Although monoclonal antibodies are used widely for cancer treatment, many patients do not sufficiently respond to monospecific therapy, thereby leading to tumor resistance. Multispecific antibodies have the potential to simultaneously address two or more different antigens, which are sufficient to target two trails involved in cancer pathogenesis, and thereby, provide advantages over monoclonal antibodies therapy. In addition, these are one-third the size of monoclonal antibodies, thus showing high penetration in cell membrane and are generally easy to manufacture.
In recent times, both bispecific and trispecific antibodies are becoming one of the most promising cancer immunotherapy options, which may offer significant advantages in cancer treatment. Currently, small companies are collaborating with larger pharmaceutical companies to launch bispecific/trispecific antibodies in the market. New generation platforms have emerged in the multispecific antibodies. Some of the recently launched new platforms include the bispecific T-cell engager (BiTE) platform, and dual-affinity re-targeting antibody (DART) platform. The emergence of such platforms to develop multispecific antibodies will drive market growth during the forecast period.
Substantial rise in number of clinical trials intended towards the development of potent and advanced bispecific drugs over the past decade has acted favorably for the growth of multispecific antibodies market. These trials have made these drugs a popular as well as promising option for enhanced treatment of various chronic conditions. At present, there are more than 300 drugs in clinical pipeline and as per our analysis 4-5 multispecific antibodies are expected to enter the market by 2023. The coming years is expected to witness rapid product launches in multispecific antibodies market which will drive the growth of market. The global bispecific antibody therapeutics market is highly fragmented, with the presence of various key players including Amgen, Abbvie, Bristol Meyer Squibb, Celegen, F-Star, and several others.
US held the maximum share in 2020 and 2021 due to presence of well-established healthcare infrastructure. Moreover, increasing government funding for cancer research and technology development is anticipated to boost the development of multispecific antibodies during the forecast period. In addition, countries in Asia-Pacific including Japan, China, India and others are expected to grow with high rates owing to presence of significant market growth opportunities, increasing research funding, rising target population base, and growing awareness of personalized therapeutics.
Contact:
Neeraj Chawla
Kuick Research
Research Head
+91-9810410366